表皮生长因子受体突变非小细胞肺癌靶向药物的研究进展

Research progress of targeted medicine for non-small cell lung cancer withr epidermal growth factor receptor mutation

肺癌是全球病死率最高的恶性肿瘤,其中85%为非小细胞肺癌(NSCLC),约40%NSCLC患者存在表皮生长因子受体(EGFR)突变,EGFR突变的靶向治疗药物终结了NSCLC药物治疗长期停滞不前的局面,EGRF靶向药物研究已成为肺癌治疗的热点,同代药物产品多样。本文汇总第一、二、三代靶向药物的经典临床研究及其进展,了解不同靶向药物的选择标准和耐药后的应对策略,以期促进靶向治疗药物的规范及合理应用。

Lung cancer is malignant tumors with the highest mortality rate in the world, of which 85% are non-small cell lung cancer(NSCLC), and about 40% of NSCLC patients have epidermal growth factor receptor(EGFR) mutations. The targeted therapeutic drugs of EGFR mutations have ended the long-term stagnation of NSCLC drug treatment. The research of drugs targeting for EGFR mutations has become a hot spot in the treatment of lung cancer, and contemporaneous drugs usually have diverse products. This paper summarizes the classic clinical research and progress of the first, second and third generation EGFR targeted drugs, and understands the selection criteria of different targeted drugs and the coping strategies after drug resistance, in order to promote the standard and rational application of targeted drugs.